Literature DB >> 11019867

Postoperative inflammation, microbial complications, and wound healing following laser in situ keratomileusis.

J L Alió1, J J Pérez-Santonja, T Tervo, K F Tabbara, M Vesaluoma, R J Smith, B Maddox, R K Maloney.   

Abstract

Although the biology of corneal wound healing is only partly understood, healing after photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) differs in many respects, and the mechanisms appear to be differently controlled. There is less of an inflammatory and healing response after LASIK, but a longer period of sensory denervation. The cellular, molecular, and neural regulatory phenomena associated with postoperative inflammation and wound healing are likely to be involved in the adverse effects after LASIK, such as flap melt, epithelial ingrowth, and regression. Interface opacities in the early postoperative period include diffuse lamellar keratitis (DLK), microbial keratitis, epithelial cells, and interface opacities. Diffuse lamellar keratitis (sands of the Sahara syndrome) describes an apparently noninfectious diffuse interface inflammation after lamellar corneal surgery probably caused by an allergic or a toxic inflammatory reaction. Noninfectious keratitis must be distinguished from microbial keratitis to avoid aggressive management and treatment with antimicrobial drugs. Microbial keratitis is a serious complication after LASIK, but a good visual outcome can be achieved following prompt and appropriate treatment.

Entities:  

Mesh:

Year:  2000        PMID: 11019867     DOI: 10.3928/1081-597X-20000901-07

Source DB:  PubMed          Journal:  J Refract Surg        ISSN: 1081-597X            Impact factor:   3.573


  8 in total

Review 1.  In vivo confocal microscopy of the human cornea.

Authors:  I Jalbert; F Stapleton; E Papas; D F Sweeney; M Coroneo
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

Review 2.  [Microbial keratitis following laser in situ keratomileusis. Prevention, differential diagnosis, and therapy].

Authors:  M Tehrani; H B Dick; G Daeschlein; A Kramer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

3.  A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK).

Authors:  Michael D Greenwood; Richard A Gorham; Keeley R Boever
Journal:  Clin Ophthalmol       Date:  2020-08-06

4.  Microbial keratitis in kingdom of bahrain: clinical and microbiology study.

Authors:  Nada Al-Yousuf
Journal:  Middle East Afr J Ophthalmol       Date:  2009-01

5.  Efficacy and tolerability of a fixed-dose moxifloxacin - dexamethasone formulation for topical prophylaxis in LASIK: a comparative, double-masked clinical trial.

Authors:  Mauro Campos; Mariana Avila; Anelise Wallau; Cristina Muccioli; Ana Luisa Höfling-Lima; Rubens Belfort
Journal:  Clin Ophthalmol       Date:  2008-06

6.  Efficacy and tolerability of a combined gatifloxacin plus prednisolone formulation for topical prophylaxis after LASIK.

Authors:  Mauro Campos; Cristina Muccioli; João Bns Malta; Rafael A Gerade; André LA Salame; Rubens Belfort
Journal:  Clin Ophthalmol       Date:  2011-02-15

7.  Proteoglycan synthesis by human corneal explants submitted to laser in situ keratomileusis (LASIK).

Authors:  Suy Anne Reboucas Martins; Mauro Q Campos; Benedicto C Vidal; Alessandra G A Berto; Jair A K Aguiar; Yara M Michelacci
Journal:  Mol Vis       Date:  2007-02-01       Impact factor: 2.367

8.  Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients.

Authors:  Steven A Nielsen; Marguerite B McDonald; Parag A Majmudar
Journal:  Clin Ophthalmol       Date:  2013-01-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.